Cardiovascular disease is the leading cause of death in the U.S. Elevated lipoprotein(a), referred to as Lp(a), is one of the lesser-known risk factors for major cardiovascular events, such as heart attack, stroke, and urgent hospitalizations due to peripheral artery disease.
The Lp(a) HORIZON study is investigating options to reduce Lp(a) levels with the goal of decreasing the risk of major cardiovascular events in people with elevated Lp(a) levels and established cardiovascular disease.
New research for treatments that reduce cardiovascular disease risk can't move forward without volunteers like you. Answer a few questions below to see if you’re eligible to participate in this study.
If you would like to speak to someone regarding this trial, first check to see if you are initially eligible through the prescreener above. If it seems that you are eligible to take part, you will be contacted by phone so we can ask you additional questions to confirm your eligibility, and you will be able to ask any questions you may have about this clinical trial. If you are not eligible based on your responses to the prescreener, you can always contact us at firstname.lastname@example.org to discuss further.